Navigation Links
Fovea Pharmaceuticals Completes EUR30M Series B Financing
Date:12/12/2007

ing pipeline of products, which will be validated in the clinic using the proceeds of this financing round," said Sander Slootweg, managing partner at Forbion Capital Partners. "We are delighted to invest in Fovea Pharmaceuticals and join an experienced and proven management team along with a very strong and committed group of investors."

In connection with the financing, Sander Slootweg will join the Board of Directors which is comprised of Antoine Papiernik (Sofinnova Partners), Tim Haines (Abingworth), Anthony Wild (Bows Pharmaceuticals) and Bernard Gilly. Bernard Gilly has been elected as Chairman of the Board.

"Fovea's unique product platform has led to the generation of a robust pipeline of promising therapeutic candidates for the treatment of front and back of the eye disorders. Clinical candidates are already in development and at least three new products are expected to progress into the clinic in 2008," commented Pr. Jose-Alain Sahel, Founder of Fovea Pharmaceuticals and Chairman of the Scientific Advisory Board. "It has been a pleasure to work with the talented and productive team at Fovea, and we all look forward to continued progress in exploiting the potential of these novel dedicated therapies."

In parallel to these clinical developments, a strong discovery platform has been implemented, leading to the identification of novel targets. Fovea Pharmaceuticals has recently signed a Research Partnership Agreement with Genzyme to develop gene related therapies on the basis of one of these programs, using Fovea's selected targets to treat major retinal dystrophies.

About FOVEA Pharmaceuticals

Fovea Pharmaceuticals SA (Fovea) is a privately-held biopharmaceutical company specialized in development and commercialization of drugs for the treatment of ocular diseases, with a special focus on retinal pathologies. Created in May 2005, Fovea has a highly experienced board and management team. Fovea has been funded by six leading E
'/>"/>

SOURCE Fovea Pharmaceuticals SA.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Biochips and Microarrays - ... This report is an analysis of ... report starts with a description of technologies as ... array comparative genomic hybridization (CGH), copy number variation ...
(Date:9/2/2015)... Sep. 02, 2015 Research ... of Jain PharmaBiotech,s new report "Gene Therapy - ... The markets for gene therapy are difficult to ... product and it is marketed in China ... for the years 2014-2024. The estimates are based on ...
(Date:9/2/2015)... ... September 02, 2015 , ... Drug companies increasingly are ... BCC Research reveals in its new report that the U.S. will generate the ... and generates the most market demand. , BCC Research examines plant-derived drugs ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, ... developing treatments for urological and related conditions, announced today ... planned private placement convertible note financing, raising a total ... tranches totaling $3.175 million. Josh ... from this private placement are intended to be used ...
Breaking Biology Technology:Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3
... RNA later is a tissue storage , ... tissues. (Ambion's new RNA later -ICE is designed ... with frozen tissues - see "<A , ... Grinding Frozen Tissue " for more information.) Tissue , ...
... , , NAVIGATE THIS ARTICLE: <A , ... <A , href="#3">RNA , ... Transfer > <A , href="#5">Hybridization, , ... href="#6">Stripping , & Reprobing , , ...
... RNA is often labeled with fluorescent , ... may be , directly incorporated during ... post-aRNA reverse transcription (RT) reaction, or attached via a , ... (post-synthesis). Direct labeling requires the enzymatic , ...
Cached Biology Technology:RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 2RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 3RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 4RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 5RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 6RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 7Northern Analysis: The Basics 2Northern Analysis: The Basics 3Northern Analysis: The Basics 4Northern Analysis: The Basics 5Northern Analysis: The Basics 6Northern Analysis: The Basics 7Northern Analysis: The Basics 8Northern Analysis: The Basics 9Northern Analysis: The Basics 10Northern Analysis: The Basics 11Northern Analysis: The Basics 12Northern Analysis: The Basics 13Northern Analysis: The Basics 14Northern Analysis: The Basics 15Northern Analysis: The Basics 16Northern Analysis: The Basics 17Northern Analysis: The Basics 18Northern Analysis: The Basics 19Amino Allyl Labeling for Array Analysis 2
(Date:8/12/2015)... Calif. , Aug. 12, 2015  Synaptics ... of human interface solutions, today announced that four ... announced Match-in-Sensor solution, have officially been named FIDO ... As part of the certification, Synaptics, Natural ID™ ... 1.0 Universal Authentication Framework (UAF) standard and are ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/5/2015)... York , August 5, 2015 ... report titled "Facial Recognition Market - Global Industry Analysis, ... the global market for facial recognition is forecast to ... driven by increased demand for surveillance systems by civil ... rising number of crimes and terrorist activities across the ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... of double-amputee Olympic hopeful Oscar Pistorius give him a clear ... more off what his 400-meter race time would be if ... released to the public for the first time ... in Dallas and Matthew Bundle of the University of Wyoming. ...
... much bigger animals, despite only having a brain the ... University of London. "Animals with bigger brains are ... of Sensory and Behavioural Ecology at Queen Mary,s Research ... Niven. This begs the important question: what are they ...
... regimens and the best efforts of nurses and doctors, about ... infections. But a revolutionary new wound dressing developed at Tel ... Meital Zilberman of TAU,s Department of Biomedical Engineering has developed ... fibers that can be loaded with drugs like antibiotics to ...
Cached Biology News:Oscar Pistorius' artificial limbs give him clear, major advantage for sprint running 2Oscar Pistorius' artificial limbs give him clear, major advantage for sprint running 3Bigger not necessarily better, when it comes to brains 2A second skin 2
... a combination of an orbital shaker and ... while providing gentle, thorough mixing without foaming. ... used for a variety of applications including ... immunoblots, staining/destaining, chromatography, etc. The VSN-5 Nutating ...
... for the rapid purification of linear 100 bp ... DNA band is excised from an,agarose gel and ... base of the column are a series of ... back while allowing DNA to selectively pass through ...
...
... The Synaptic Vesicles Isolation Kit provides ... an enriched synaptic vesicle fraction. The ... lysis of the synaptosomes, and differential ... gradient. The kit also contains an ...
Biology Products: